Abstract
Finding new applications for existing pharmaceuticals, known as drug repositioning, is a validated strategy for resolving the problem of high expenditure but low productivity in drug discovery. Currently, the prevalent computational methods for drug repositioning are focused mainly on the similarity or relevance between known drugs based on their “features”, including chemical structure, side effects, gene expression profile, and/or chemical-protein interactome. However, such drug-oriented methods may constrain the newly predicted functions to the pharmacological functional space of the existing drugs. Clinically, many drugs have been found to bind “off-target” (i.e. to receptors other than their primary targets), which can lead to undesirable effects. In this study, which integrates known drug target information, we propose a disease-oriented strategy for evaluating the relationship between drugs and disease based on their pathway profile. The basic hypothesis of this method is that drugs exerting a therapeutic effect may not only directly target the disease-related proteins but also modulate the pathways involved in the pathological process. Upon testing eight of the global best-selling drugs in 2010 (each with more than three targets), the FDA (Food and Drug Administration, USA)-approved therapeutic function of each was included in the top 10 predicted indications. On average, 60% of predicted results made using our method are proved by literature. This approach could be used to complement existing methods and may provide a new perspective in drug repositioning and side effect evaluation.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Adams C P, Brantner V V. Estimating the cost of new drug development: Is it really 802 million dollars? Health Aff (Millwood), 2006, 25: 420–428
Krantz A. Protein-site targeting. Diversification of the drug discovery process. Nat Biotechnol, 1998, 16: 1294
Day M. The bitterest pill. Nurs Times, 1996, 92: 16–17
Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov, 2004, 3: 711–715
Calabrese L, Fleischer A B. Thalidomide: Current and potential clinical applications. Am J Med, 2000, 108: 487–495
Amato R J. Thalidomide: An antineoplastic agent. Curr Oncol Rep, 2002, 4: 56–62
Matthews S J, McCoy C. Thalidomide: A review of approved and investigational uses. Clin Ther, 2003, 25: 342–395
Gasparini G, Morabito A, Magnani E, et al. Thalidomide: An old sedative-hypnotic with anticancer activity? Curr Opin Investig Drugs, 2001, 2: 1302–1308
Ashburn T T, Thor K B. Drug repositioning: Identifying and developing new uses for existing drugs. Nat Rev Drug Discov, 2004, 3: 673–683
Chong C R, Sullivan D J Jr. New uses for old drugs. Nature, 2007, 448: 645–646
Keiser M J, Setola V, Irwin J J, et al. Predicting new molecular targets for known drugs. Nature, 2009, 462: 175–181
Campillos M, Kuhn M, Gavin A C, et al. Drug target identification using side-effect similarity. Science, 2008, 321: 263–266
Iorio F, Bosotti R, Scacheri E, et al. Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc Natl Acad Sci USA, 2010, 107: 14621–14626
He L, Luo H, Chen J, et al. DRAR-CPI: A server for identifying drug repositioning potential and adverse drug reactions via the chemical-protein interactome. Nucleic Acids Res, 2011, 39: W492–W498
Drews J. Drug discovery: A historical perspective. Science, 2000, 287: 1960–1964
Paolini G V, Shapland R H, van Hoorn W P, et al. Global mapping of pharmacological space. Nat Biotechnol, 2006, 24: 805–815
Barabasi A L, Oltvai Z N. Network biology: Understanding the cell’s functional organization. Nat Rev Genet, 2004, 5: 101–113
Barabasi A L, Gulbahce N, Loscalzo J. Network medicine: A network-based approach to human disease. Nat Rev Genet, 2011, 12: 56–68
Kanehisa M, Goto S, Furumichi M, et al. KEGG for representation and analysis of molecular networks involving diseases and drugs. Nucleic Acids Res, 2010, 38: D355–360
Li Y, Agarwal P. A pathway-based view of human diseases and disease relationships. PLoS ONE, 2009, 4: e4346
Davis A P, King B L, Mockus S, et al. The comparative toxicogenomics database: Update 2011. Nucleic Acids Res, 2011, 39: D1067–1072
Feldman S R, Kimball A B, Krueger G G, et al. Etanercept improves the health-related quality of life of patients with psoriasis: Results of a phase III randomized clinical trial. J Am Acad Dermatol, 2005, 53: 887–889
De Smit M J, Brouwer E, Vissink A, et al. Rheumatoid arthritis and periodontitis: A possible link via citrullination. Anaerobe, 2011, 17: 196–200
Berthelot J M, Le Goff B. Rheumatoid arthritis and periodontal disease. Joint Bone Spine, 2010, 77: 537–541
Di Paola R, Mazzon E, Muia C, et al. Effects of etanercept, a tumour necrosis factor-alpha antagonist, in an experimental model of periodontitis in rats. Br J Pharmacol, 2007, 150: 286–297
Swale V J, Perrett C M, Denton C P, et al. Etanercept-induced systemic lupus erythematosus. Clin Exp Dermatol, 2003, 28: 604–607
Kang M J, Lee Y H, Lee J. Etanercept-induced systemic lupus erythematosus in a patient with rheumatoid arthritis. J Korean Med Sci, 2006, 21: 946–949
Shakoor N, Michalska M, Harris C A, et al. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet, 2002, 359: 579–580
Madhusudan S, Foster M, Muthuramalingam S R, et al. A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer. Clin Cancer Res, 2004, 10: 6528–6534
Chernyshov V P, Vodyanik M A, Pisareva S P. Lack of soluble TNF-receptors in women with recurrent spontaneous abortion and possibility for its correction. Am J Reprod Immunol, 2005, 54: 284–291
Winger E E, Reed J L. Treatment with tumor necrosis factor inhibitors and intravenous immunoglobulin improves live birth rates in women with recurrent spontaneous abortion. Am J Reprod Immunol, 2008, 60: 8–16
Rodas J D, Cairo C, Djavani M, et al. Circulating natural killer and gammadelta T cells decrease soon after infection of rhesus macaques with lymphocytic choriomeningitis virus. Mem Inst Oswaldo Cruz, 2009, 104: 583–591
Wallace D J. The use of etanercept and other tumor necrosis factor-alpha blockers in infertility: It’s time to get serious. J Rheumatol, 2003, 30: 1897–1899
Nabors L B, Suswam E, Huang Y, et al. Tumor necrosis factor alpha induces angiogenic factor up-regulation in malignant glioma cells: A role for RNA stabilization and HuR. Cancer Res, 2003, 63: 4181–4187
Lazner F, Gowen M, Pavasovic D, et al. Osteopetrosis and osteoporosis: Two sides of the same coin. Hum Mol Genet, 1999, 8: 1839–1846
Boyce B F, Li P, Yao Z, et al. TNF-alpha and pathologic bone resorption. Keio J Med, 2005, 54: 127–131
Depinay N, Franetich J F, Gruner A C, et al. Inhibitory effect of TNF-alpha on malaria pre-erythrocytic stage development: Influence of host hepatocyte/parasite combinations. PLoS ONE, 2011, 6: e17464
Maihle N J, Baron A T, Barrette B A, et al. EGF/ErbB receptor family in ovarian cancer. Cancer Treat Res, 2002, 107: 247–258
Andersson U, Schwartzbaum J, Wiklund F, et al. A comprehensive study of the association between the EGFR and ERBB2 genes and glioma risk. Acta Oncol, 2010, 49: 767–775
Ratushny V, Astsaturov I, Burtness B A, et al. Targeting EGFR resistance networks in head and neck cancer. Cell Signal, 2009, 21: 1255–1268
Begnami M D, Fukuda E, Fregnani J H, et al. HER2 and HER3 are Predictors of poor outcome. J Clin Oncol, 2011, 29: 3030–3036
Delord J P, Quideau S, Rochaix P, et al. Trastuzumab induced in vivo tissue remodelling associated in vitro with inhibition of the active forms of AKT and PTEN and RhoB induction in an ovarian carcinoma model. Br J Cancer, 2010, 103: 61–72
Mineo J F, Bordron A, Quintin-Roue I, et al. Recombinant humanised anti-HER2/neu antibody (Herceptin) induces cellular death of glioblastomas. Br J Cancer, 2004, 91: 1195–1199
Kondo N, Ishiguro Y, Kimura M, et al. Antitumor effect of gefitinib on head and neck squamous cell carcinoma enhanced by trastuzumab. Oncol Rep, 2008, 20: 373–378
Albarello L, Pecciarini L, Doglioni C. HER2 testing in gastric cancer. Adv Anat Pathol, 2011, 18: 53–59
Azzoli C G, Krug L M, Miller V A, et al. Trastuzumab in the treatment of non-small cell lung cancer. Semin Oncol, 2002, 29: 59–65
Langer C J, Stephenson P, Thor A, et al. Trastuzumab in the treatment of advanced non-small-cell lung cancer: Is there a role? Focus on Eastern Cooperative Oncology Group study 2598. J Clin Oncol, 2004, 22: 1180–1187
Ferrone M, Motl S E. Trastuzumab for the treatment of non-small-cell lung cancer. Ann Pharmacother, 2003, 37: 1904–1908
John J, Woodward D B, Wang Y, et al. Troponin-I as a prognosticator of mortality in severe sepsis patients. J Crit Care, 2010, 25: 270–275
Telli M L, Witteles R M. Trastuzumab-related cardiac dysfunction. J Natl Compr Canc Netw, 2011, 9: 243–249
Gay S, Gay R E, Koopman W J. Molecular and cellular mechanisms of joint destruction in rheumatoid arthritis: Two cellular mechanisms explain joint destruction? Ann Rheum Dis, 1993, 52: S39–S47
Satoh K, Kikuchi S, Sekimata M, et al. Involvement of ErbB-2 in rheumatoid synovial cell growth. Arthritis Rheum, 2001, 44: 260–265
Manger K, Repp R, Jansen M, et al. Fcgamma receptor IIa, IIIa, and IIIb polymorphisms in German patients with systemic lupus erythematosus: Association with clinical symptoms. Ann Rheum Dis, 2002, 61: 786–792
Brambila-Tapia A J, Davalos-Rodriguez I P. Fcgamma receptor polymorphisms and systemic lupus erythematosus. Rev Invest Clin, 2009, 61: 66–72
Wolf D L, Neiderud A M, Hinckley K, et al. Fcgamma receptor polymorphisms and periodontal status: A prospective follow-up study. J Clin Periodontol, 2006, 33: 691–698
Yamamoto K, Kobayashi T, Grossi S, et al. Association of Fcgamma receptor IIa genotype with chronic periodontitis in Caucasians. J Periodontol, 2004, 75: 517–522
Loos B G, Leppers-Van de Straat F G, Van de Winkel J G, et al. Fcgamma receptor polymorphisms in relation to periodontitis. J Clin Periodontol, 2003, 30: 595–602
Musolino A, Naldi N, Bortesi B, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol, 2008, 26: 1789–1796
Erickson C A, Stigler K A, Posey D J, et al. Aripiprazole in autism spectrum disorders and fragile X syndrome. Neurotherapeutics, 2010, 7: 258–263
Pardini M, Guida S, Gialloreti L E. Aripiprazole treatment for coprophagia in autistic disorder. J Neuropsychiatry Clin Neurosci, 2010, 22: e433–451
Blankenship K, Erickson C A, Stigler K A, et al. Aripiprazole for irritability associated with autistic disorder in children and adolescents aged 6–17 years. Ped Health, 2010, 4: 375–381
Marcus R N, Owen R, Manos G, et al. Aripiprazole in the treatment of irritability in pediatric patients (aged 6–17 years) with autistic disorder: results from a 52-week, open-label study. J Child Adolesc Psychopharmacol, 2011, 21: 229–236
Owen R, Sikich L, Marcus R N, et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics, 2009, 124: 1533–1540
Robb A S, Andersson C, Bellocchio E E, et al. Safety and tolerability of aripiprazole in the treatment of irritability associated with autistic disorder in pediatric subjects (6–17 years old): Results from a pooled analysis of 2 studies. Prim Care Companion CNS Disord, 2011, 13: PCC.10m01008
Findling R L, Short E J, Leskovec T, et al. Aripiprazole in children with attention-deficit/hyperactivity disorder. J Child Adol Psycho-pharmacol, 2008, 18: 347–354
Del Zompo M. Dopaminergic hypersensitivity in migraine: Clinical and genetic evidence. Funct Neurol, 2000, 15: 163–170
Cubo E, Kompoliti K, Leurgans S E, et al. Dopaminergic hypersensitivity in patients with Parkinson disease and migraine. Clin Neuropharmacol, 2004, 27: 30–32
LaPorta L D. Relief from migraine headache with aripiprazole treatment. Headache, 2007, 47: 922–926
Maytal G, Ostacher M, Stern T A. Aripiprazole-related tardive dyskinesia. CNS Spectr, 2006, 11: 435–439
Abbasian C, Power P. A case of aripiprazole and tardive dyskinesia. J Psychopharmacol, 2009, 23: 214–215
Pena M S, Yaltho T C, Jankovic J. Tardive dyskinesia and other movement disorders secondary to aripiprazole. Mov Disord, 2011, 26: 147–152
Kanatous S B, Mammen P P A, Rosenberg P B, et al. Hypoxia reprograms calcium signaling and regulates myoglobin expression. Cell Physiol, 2009, 296: C393–C402
Zhang J Y, Kowal D M, Nawoschik S P, et al. Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms. Biochem Pharmacol, 2006, 71: 521–529
Author information
Authors and Affiliations
Corresponding authors
Additional information
This article is published with open access at Springerlink.com
Electronic supplementary material
Rights and permissions
This article is published under an open access license. Please check the 'Copyright Information' section either on this page or in the PDF for details of this license and what re-use is permitted. If your intended use exceeds what is permitted by the license or if you are unable to locate the licence and re-use information, please contact the Rights and Permissions team.
About this article
Cite this article
Ye, H., Yang, L., Cao, Z. et al. A pathway profile-based method for drug repositioning. Chin. Sci. Bull. 57, 2106–2112 (2012). https://doi.org/10.1007/s11434-012-4982-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11434-012-4982-9